There is little evidence on which to judge the optimal treatment for convulsive status epilepticus (CSE) in children. This study compares the effect of intravenous (iv) lorazepam with iv diazepam as the firs line of treatment of CSE. We studied all children with prolonged seizures arriving in the Accident and Emergency (A&E) Department in two separate periods. In the firs 6-month period iv diazepam was used as standard treatment, in the second 1-year period iv lorazepam was used. We measured latency to stopping of seizure and any adverse events. A successful treatment was define as one in which the seizure clinically ceased within 15 minutes after siting the iv cannula, requiring no further treatment. Intravenous diazepam (0.32 mg kg −1 ) was used in 17 of 26 patients, whilst iv lorazepam (0.13 mg kg −1 ) was used in 31 of 59. There were no differences between the two groups regarding age, sex and seizure type. The seizure was successfully controlled 15 minutes after siting the iv cannula in 11 (65%) patients treated with diazepam (median time of 3 minutes) and in 20 (65%) patients treated with lorazepam (median time of 5 minutes). These preliminary results suggest that iv lorazepam may be as effective as iv diazepam.
INTRODUCTION
For many years diazepam has been used as the firs line treatment for convulsive status epilepticus (CSE). However recently many Accident & Emergency (A&E) Departments have started using lorazepam for children as the firs treatment, in accordance with the current Advanced Paediatric Life Support protocol 1 , and the recent evidence-based guidelines from the British Paediatric Neurology Association 2 .
Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged CSE. There is evidence that the longer the convulsion the more difficul it may be to treat 3 and there is also a greater risk of long-term neurological sequelae 4 . Lorazepam is preferred as it has a longer half-life, possibly less respiratory depression [5] [6] [7] , and repeated doses are less often required than with diazepam 8 .
AIMS
In view of these considerations the CSE protocol at the Birmingham Children's Hospital A&E Department was changed to include intravenous (iv) lorazepam as the firs line treatment. An audit of this protocol change was then undertaken to compare the effica y and safety of iv diazepam with iv lorazepam.
MATERIALS AND METHODS
Data was collected over two separate periods. The firs 6-month period was from September 1997 to March 1998. The second 1-year period was from March 1999 to March 2000. The study took place in the A&E Department at Birmingham Children's Hospital. Data collection sheets were devised and nursing staff and doctors were informed of the ongoing audit. Each time a patient came in to the department still in CSE, requiring emergency treatment, the data sheet was completed.
During the firs time period the protocol fir t line treatment was iv diazepam 0.3 mg kg −1 and in the second period the protocol firs line treatment was iv lorazepam 0.1 mg kg −1 . A repeat dose of the same amount was to be given after 10 minutes if there had been no response (see Figs 1 and 2 ). A successful treatment was define as one in which the seizure clinically ceased within 15 minutes after siting the iv cannula, requiring no further treatment. Each patient's vital signs were monitored, particularly signs of respiratory depression. The patient's age and sex, length of seizure prior to admission, time of admission to A&E, times of administration of drugs, latency to clinically evident seizure control, any recurrence of seizure or need for admission to paediatric intensive care (PICU) were noted prospectively on a data sheet. If initial treatment was unsuccessful the next steps in the protocol were followed which were iv phenytoin at 18 mg kg Statistical analysis, comparing the latency times to control seizure, in the two groups was undertaken using the Mann-Whitney test as the times had skewed distributions. Medians and ranges are presented as summary statistics.
RESULTS
The ages of the children in the two groups were similar: the mean age of children given diazepam (group 1) was 3.5 years and for the lorazepam (group 2) was 4.2 years ( Table 1 ). The protocol change and the longer time period meant that there were more children in group 2, 31 compared with 17 in group 1. Fifty-six% of the diazepam group and 59% of the lorazepam group received rectal diazepam en route to the hospital by the paramedic crew.
The mean iv doses were: 0.32 mg kg −1 of diazepam and 0.13 mg kg −1 of lorazepam. The seizure was successfully controlled in 65% of patients treated with diazepam and in 65% treated with lorazepam (i.e. the seizure ceased within 15 minutes after siting the iv cannula and required no further treatment (see Table 2 )). A greater proportion (53%) of the convulsions stopped in the firs 5 minutes with diazepam compared with lorazepam (42%) ( Table 3) . This difference is not signifi ant.
In those patients who required only a single dose of iv treatment to control their seizure, the median latency for diazepam (n = 11) was 3 minutes and that of lorazepam (n = 16) was 5 minutes in this study. There were no statistically significan differences between groups in respect of any the above times.
There were two patients admitted to PICU following diazepam (12%) and six following lorazepam (19%). Admission to PICU was either because the seizure required thiopentone induction (one child in each group) or for observation after the prolonged convulsion with concern about respiratory depression (three children in the lorazepam group), or because the patient was intubated and ventilated, or for management of concomitant circulatory or respiratory failure (one child in both groups had meningitis requiring PICU care).
There were no other associated adverse events. Seizures recurred in one of 12 (8%) patients successfully treated with diazepam and in four of 20 (20%) patients treated with lorazepam. These are not statistically significantl different. There were no deaths in the study population. The presumed aetiology of the convulsions was similar in both groups (Table 4) . 
DISCUSSION
There are difficultie in the methodology of such a comparative audit. We compared data collected in two different time periods with different observers and different numbers of patients. Looking at the figure it seems that lorazepam may have been as effective as diazepam, although it may not be as rapid as diazepam. The data was analysed statistically using non-parametric tests. It was found that there was no statistically significan difference between the two groups for effica y or safety. Interestingly different studies have found a range of latency of action for lorazepam. Table 5 shows the studies involving children. An adult study (Homan et al. 10 ) found diazepam to have a median latency of 2 minutes and lorazepam of 3 minutes. They found in their literature review that most authors had quoted a latency of less than 11 77 patients 79% iv LOR Lacey et al. (1985) 9 31 patients 85% iv LOR Median 10 min 3 minutes for lorazepam; the longest latency they found was 15 minutes. In most studies both drugs were given as a single iv injection over a period of 0.2-2 minutes, as in our audit.
As far as overall success rate is concerned our figur of 65% is less than in the quoted studies. There were no unexpected adverse effects noted in either group, however in both groups children were admitted to PICU.
In view of the relatively low power of the study it was not possible to detect small differences in the effica y of the treatments being compared. In order to detect a difference of 15 minutes in the mean stopping time with a power of 80% and a significanc of 0.05, a sample size of 56 patients for each group would be required even with unskewed normal data. With our sample size it would only be possible to demonstrate a statistically significan difference in mean stopping time of 25 minutes or more (80% power, P = 0.05).
With the large variability in the stopping times the distribution is skewed to the right, necessitating even larger sample sizes to detect moderate differences.
However the other outcomes suggest that there is not a clinically significan difference in effica y, e.g. in terms of relapse rate or admission to PICU.
From this audit we can conclude that lorazepam seems at least as safe and effective as diazepam in the treatment of convulsive status epilepticus. An important point to emerge from this comparative audit is that there were no adverse events associated with the new protocol. This has allowed us to continue to use iv lorazepam in the A&E Department with continuing audit of outcome.
